Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X:
“In our Annals of Oncology review we collected (see supplementary figure S6) available PK of trastuzumab-based ADCs with different drug-linkers compared to ‘naked’ trastuzumab!”
Title: Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
Authors: R. Colombo, S. D. Seredick, S. D. Barnscher, J. R. Rich
Other articles about Annals of Oncology on OncoDaily.